Hypnion’s Insomnia Drug Shows Promise

U.S. firm Hypnion said Friday its insomnia treatment HY10275 improved sleep in a phase 2 trial.

HY10275 could represent a major improvement in the treatment of insomnia as a safe, non-scheduled and well tolerated medication with superior sleep maintenance efficacy and comparable sleep onset efficacy to currently used medications, said John Dee, Hypnion’s president and chief executive officer.

We are very encouraged by the outcome of this initial phase 2 trial, which demonstrates proof of concept for both efficacy and safety of HY10275, Dee added. The pharmacodymamic and pharmacokinetic profile of the drug coupled with its unique mechanism of action offers strong promise as a highly differentiated therapeutic.

In the trial, which involved 52 patients, HY10275 delivered significant improvements in wake after sleep onset in a dose-dependent manner. Patients with moderate to severe insomnia responded as well as those with mild to moderate symptoms.

No adverse events were attributed to treatment, and no subjects reported next-day impairment or residual fatigue.